Introduction {#S0001}
============

Chronic kidney disease (CKD), which prevalence is still growing worldwide, confers a higher risk of coronary artery disease (CAD), chronic heart failure (CHF) and/or death independently of conventional cardiovascular risk factors \[[@CIT0001]--[@CIT0004]\]. In CKD patients left ventricular (LV) diastolic dysfunction occurs frequently and is associated with heart failure (HF) and higher mortality \[[@CIT0005]\]. Other studies demonstrated that CKD severity was the most independent predictor of elevated LV filling pressure and could be responsible for impaired systolic and diastolic functions in predialysis CKD \[[@CIT0006]\]. Left ventricular diastolic dysfunction is observed even in patients with early stages of chronic kidney dysfunction \[[@CIT0007]\]. It was estimated that 15% of patients starting dialysis therapy have systolic dysfunction of the left ventricle while the prevalence of diastolic dysfunction at dialysis inception is much higher. Either systolic or diastolic dysfunction can lead to clinically evident congestive heart failure \[[@CIT0008]\]. Left ventricular systolic dysfunction is often associated with severe CAD and it is a major determinant of prognosis \[[@CIT0009]\]. Left ventricular diastolic dysfunction in CKD patients is of complex nature. According to studies, it may be influenced by the increase in LV preload due to progression of CKD stage \[[@CIT0010]\]. Also LV hypertrophy, CAD, microvascular abnormalities, interstitial fibrosis, altered fluid and electrolyte metabolism and neurohumoral alterations might contribute to the development of LV diastolic dysfunction in patients with CKD \[[@CIT0011]\]. Over-activation of the rennin--angiotensin--aldosterone system (RAAS) might play an important role in the pathomechanism since even a mild CKD results in early cardiac fibrosis with mild LV diastolic impairment and preserved systolic function \[[@CIT0012]\].

Therefore the aim of this study was to assess indices of LV echocardiographic indices in CKD patients including those on dialysis since the relationships between the echocardiographic parameters and renal function have not been fully examined.

Material and methods {#S0002}
====================

This is a cross-sectional analysis of a population of CKD patients. The study included 118 patients from the Department of Nephrology, Hypertension and Family Medicine and the Dialysis Centre, WAM University Hospital of Lodz. The enrolled patients were categorized into the following CKD subgroups: stage II (*n* = 25), stage III (*n* = 30); stage IV (*n* = 28); and stage V/dialysis (*n* = 35). All patients signed informed consent form. Exclusion criteria were as follows: state after kidney transplantation, haemoglobin \< 8 g/dl, active cancer or cancer diagnosed in the past, active hepatitis B or C, in an interview or repeatedly elevated blood levels of transaminases: alanine transaminase (ALT), aspartate transaminase (AST) alcoholism, malnutrition, HIV infection or other immune disorders, connective tissue diseases, therapy with immunosuppressive drugs, significant arrhythmias, state after implantation of heart pacemaker (CRT, ICD), history of venous thrombosis or pulmonary embolism, hyperthyroidism and hypothyroidism, hemodynamically significant heart disease, ejection fraction (EF) \< 45%, hypertrophic cardiomyopathy obesity, lack of consent to participate in the study. Criteria for inclusion in the study according to the criteria for the recognition KDOQI CKD and the recommendations of the ESC section of Echocardiography in 2009 on the recognition of diastolic dysfunction of the left ventricle.

All patients underwent transthoracic echocardiography (TTE) using Aloka ProSound Alpha camera 10. Measurements were made in the M-dimensional and two-dimensional 2D presentation. Flow parameters were evaluated using Doppler (continuous wave method -- CW, pulse method- PM and tagged color method) and TDI. In the study, the following indices were assessed: size of the left atrium (LA), end-diastolic dimension of intraventricular septum (IVSd), left ventricle (LVIDd) and left ventricle posterior wall of the (PWd). The results of these measurements were used to evaluate left ventricular ejection fraction (EF%) indicating LV systolic function and left ventricular mass index (LVMI). Characteristics of mitral inflow is the simplest and most commonly used technique for the assessment of diastolic function. The spectrum of mitral inflow was recorded using pulsed Doppler examination with Doppler gate placed at the end of mitral leaflets in apical 4-chamber view. Diastolic function was assessed by determining the velocities of early (E) and late (A) diastolic transmitral flow, the ratio E-to-A (E/A), deceleration time (DT), isovolumic relaxation time (IVRT) and pulmonary vein flow velocities. Indices of LV diastolic function were analysed depending on the severity of CKD in the study groups. On the basis of the aforementioned parameters three basic types of diastolic dysfunction: impaired relaxation (mild diastolic dysfunction with usually normal LV filling pressure at rest), pseudonormalization (moderate diastolic dysfunction with mildly or moderately elevated LV filling pressure) and restriction (severe diastolic dysfunction characterized by significantly elevated LV filling pressure) were distinguished. In dialysis patients the examination was carried out before and after dialysis. The severity of diastolic dysfunction is mirrored by the increase in LV filling pressure associated with a decrease in LV susceptibility due to the exacerbation of LV fibrosis and the increase in the stiffness of cardiomyocytes themselves. Results of echocardiographic examination were confirmed by tissue Doppler methods which could detect the subtle changes of diastolic function due to kidney dysfunction. Tissue Doppler was used since this method is less dependent on volume load in CKD patients. Echocardiographic examination was performed in accordance with the recommendations of the ESC section of Echocardiography of 2009.

Statistical analysis {#S20003}
--------------------

Data are presented as mean ± standard deviation (SD). Shapiro-Wilk test was used to assess the normality of variables' distribution. Homogeneity of variance was checked with Levene\'s test. In case of a normal distribution and no differences in variances, the significance of differences between the two groups was assessed using paired sample *t-*test, and if at least one of the aforementioned criteria was not met Wilcoxon test was used.

Results {#S0004}
=======

The mean age of patients with CKD II--IV was 63.97 ±12.5 years and 67.78 ±12.0 in dialysis group. There were more males in dialysis group than in other CKD group (68.57% vs. 30.12%). In dialysis group hypertension (93.1% vs. 85.54%) and lipid disorders (97.5% vs. 87.95%) were more frequent in comparison to CKD stages II--IV. The frequency of treatment with β-blockers and Ca-channel blockers was similar in CKD II--IV and dialysis patients. Hemodialysis (HD) patient more rarely used angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs). None of patients was treated with Ivabradin, Ranolazin or NO-donors. Diastolic dysfunction of right ventricle was also observed. Demographic characteristic is presented in [Table I](#T0001){ref-type="table"}. Subjects with hypertension were more likely to have atrial fibrillation, increased diameter of LA, increased atrial volume before dialysis and decreased after it as well as reduced early diastolic velocity (E') and ejection fraction (data not shown).

###### 

Demographic characteristic of study groups

  Parameter                           Stage II--IV   V/Dialysis
  ----------------------------------- -------------- -------------
  Sex, male (%)                       30.12          68.57
  Age \[years\]                       63.97 ±12.5    67.78 ±12.0
  Hypertension (%)                    85.54          93.1
  Lipid disorders (%)                 87.95          97.5
  Diabetes (%)                        28.92          25.6
  ACE-I treatment (%)                 31             49
  β-blockers treatment (%)            42             45
  ARBs treatment (%)                  10             23
  Ca-channel blockers treatment (%)   63             57

The analysis of echocardiographic parameters showed that in CKD patients the stage of renal failure was associated with the significant increase in LV mass (268.0 ±47.6 CKD I/II vs. 287.8 ±70.3 CKD III vs. 298.1 ±86.0 CKD IV vs. 432.7 ±122.4 CKD V/dialysis, *p* \< 0.0001), IVSd (13.0 (12.0--14.2) in CKD I/II vs. 16.0 (15.0--17.0) in CKD V/dialysis, *p* \< 0.0001), IVSs (15.0 (14.7--17.0) in CKD I/II vs. 18.0 (18.0--19.0) in CKD V/dialysis, systolic LV (37.3 ±4.5 vs. 51.2 ±8.9, *p* \< 0.0001) and diastolic LV (CKD I--II 44.7 ±4.1 vs. CKD III 48.5 ±6.7 vs. CKD IV 47.1 ±5.6; *p* = 0.004) dimensions and in the size of the LA (40.4 ±2.0 vs. 41.9 ±2.7 vs. 42.3 ±3.2 vs. 44.8 ±3.1; *p* \< 0.0001). Moreover, the increase in the E/E' ratio between groups of patients (6.7 ±1.5 vs. 8.9 ±2.4 vs. 11.5 ±4.0 vs. 13.5 ±5.0; *p* \< 0.0001) was seen in this study. The reduction in deceleration time (247.2 ±34.5 in CKD I/II vs. 225.6 ±43.2 in CKD III vs. 197.4 ±61.0 in CKD IV, *p* = 0.0005) along with decreased estimated glomerular filtration rate (eGFR) was also observed in this study. The results of echocardiographic examination are summarized in [Table II](#T0002){ref-type="table"}.

###### 

Echocardiographic examination results

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                          II stage\                                                                                                                III stage\                                           IV stage\                                                                      V stage/dialysis (*n* = 35)   Value of *p*
                                                     (*n* = 25)                                                                                                               (*n* = 30)                                           (*n* = 28)                                                                                                   
  -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------- --------------
  IVSd \[mm\]                                        13.0 (12.0--14.2)[9](#TF0009){ref-type="table-fn"}                                                                       13.0 (12.0--13.2)[9](#TF0009){ref-type="table-fn"}   13.0 (12.0--14.7)[9](#TF0009){ref-type="table-fn"}                             16.0 (15.0--17.0)             \< 0.0001

  IVSs \[mm\]                                        15.0 (14.7--17.0)[9](#TF0009){ref-type="table-fn"}                                                                       16.0 (14.0--16.2)[9](#TF0009){ref-type="table-fn"}   16.0 (14.2--17.7)[9](#TF0009){ref-type="table-fn"}                             18.0 (18.0--19.0)             \< 0.0001

  LV mass \[g\]                                      268.0 ±47.6[9](#TF0009){ref-type="table-fn"}                                                                             287.8 ±70.3[9](#TF0009){ref-type="table-fn"}         298.1 ±86.0[9](#TF0009){ref-type="table-fn"}                                   432.7 ±122.4                  \< 0.0001

  LV hypertrophy                                     25 (100%)                                                                                                                30 (100%)                                            28 (100%)                                                                      30 (100%)                     NS

  LV systolic \[mm\]                                 37.3 ±4.5[9](#TF0009){ref-type="table-fn"}                                                                               41.0 ±6.2[9](#TF0009){ref-type="table-fn"}           38.9 ±6.2[9](#TF0009){ref-type="table-fn"}                                     51.2 ±8.9                     \< 0.0001

  LV diastolic \[mm\]                                44.7 ±4.1                                                                                                                48.5 ±6.7[8](#TF0008){ref-type="table-fn"}           47.1 ±5.6[7](#TF0007){ref-type="table-fn"}                                     43.1 ±8.8                     0.004

  LA diameter \[mm\]                                 40.4 ±2.0[5](#TF0005){ref-type="table-fn"},[9](#TF0009){ref-type="table-fn"}                                             41.9 ±2.7[9](#TF0009){ref-type="table-fn"}           42.3 ±3.2                                                                      44.8 ±3.1                     \< 0.0001

  RV diameter \[mm\]                                 25.9 ±2.5[9](#TF0009){ref-type="table-fn"}                                                                               26.8 ±4.0[8](#TF0008){ref-type="table-fn"}           26.5 ±2.9[9](#TF0009){ref-type="table-fn"}                                     29.9 ±2.9                     \< 0.0001

  E/E'                                               6.7 ±1.5                                                                                                                 8.9 ±2.4[1](#TF0001){ref-type="table-fn"}            11.5 ±4.0[3](#TF0003){ref-type="table-fn"},[5](#TF0005){ref-type="table-fn"}   13.5 ±5.0                     \< 0.0001

  E/A                                                0.80 (0.75--0.90)                                                                                                        0.80 (0.70--0.90)[8](#TF0008){ref-type="table-fn"}   0.80 (0.60--1.20)                                                              0.96 (0.81--1.31)             0.007

  Deceleration time \[ms\]                           247.2 ±34.5[6](#TF0006){ref-type="table-fn"}                                                                             225.6 ±43.2                                          197.4 ±61.0[7](#TF0007){ref-type="table-fn"}                                   269.0 ±135.6                  0.0005

  Diastolic disturbances (relaxation disturbances)   24 (96.0%)                                                                                                               29 (96.7%)[4](#TF0004){ref-type="table-fn"}          22 (78.6%)[8](#TF0008){ref-type="table-fn"}                                    19 (54.29%)                   0.005

  EF%                                                56.0 (55.0--60.0)[1](#TF0001){ref-type="table-fn"},[4](#TF0004){ref-type="table-fn"},[9](#TF0009){ref-type="table-fn"}   50.0 (50.0--55.0)[9](#TF0009){ref-type="table-fn"}   50.0 (50.0--55.0)[9](#TF0009){ref-type="table-fn"}                             45.0 (40.0--50.0)             \< 0.0001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

p \< 0.05

p \< 0.01

p \< 0.001 in comparison to stage III

p \< 0.05

p \< 0.01

p \< 0.001 in comparison to stage IV

p \< 0.05

p \< 0.01

p \< 0.001 in comparison to stage V.

When echocardiographic indices were compared before and after the dialysis, only E/E' differ significantly (13.5 ±5.0 before dialysis vs. 10.2 ±4.7 after dialysis; *p* = 0.002). The rest of indices seems to remain unaffected by renal replacement treatment. Examination results are presented in [Table III](#T0003){ref-type="table"}.

###### 

Results of comparison of echocardiographic indices before and after dialysis

  Parameter                 Pre-HD           Post-HD          Value of *p*
  ------------------------- ---------------- ---------------- --------------
  Left atrial volume VLA    34.9 ±21.1       34.4 ±20.9       NS
  Right atrial volume VRA   31.4 ±19.6       30.5 ±18.0       NS
  E' (LV)                   9.4 ±4.0         9.0 ±4.7         NS
  E/E' (LV)                 13.5 ±5.0        10.2 ±4.7        0.002
  E' (RV)                   12.5 ±5.4        12.5 ±5.4        NS
  E/E' (RV)                 8.0 ±5.0         8.3 ±6.0         NS
  E/A (LV)                  0.8 (0.7--0.9)   0.8 (0.8--0.9)   NS
  SPAP                      27.0 ±17.2       27.0 ±17.2       NS

Discussion {#S0005}
==========

The analysis of echocardiographic parameters in this study showed that in CKD patients increasing stage of renal failure was associated with the significant increase in both systolic and diastolic left ventricular dimensions and in the size of the left atrium. All these three parameters were greater in CKD stage V/dialysis and lowest in stage II. In more than half of the patients with formed arteriovenous fistula increased left ventricle end-diastolic dimension and worsening of diastolic function (shortening of deceleration time, E wave, the increase in E/A) were observed. Moreover, in agreement with Parfrey *et al*. \[[@CIT0013]\] study, it has been observed that shortly after the dialysis session, a reduction in diastolic diameter of the LV and an increase in the thickness of the LV wall occur which is associated with volume depletion by ultrafiltration (data not shown). Also, in this study, the RV diameter was found to be much greater in CKD patients stage V/dialysis (29.9 ±2.9) than in stages II--IV. Additionally, steady growth of interventricular septal thickness in end diastole and systole as well as the increase of LV muscle mass were observed in CKD patients along with the rising CKD stage. Left ventricular muscle mass was over 1.5-times higher in dialysis patients that in CKD stage II subjects. According to Zoccali *et al*. \[[@CIT0014]\] the increase in mass of 1 g/m 2.7/month was associated with a 62% increase in the incident risk of fatal and non-fatal cardiovascular events in dialysis patients. They also suggested that changes in LV mass index represent a stronger predictor of mortality and cardiovascular complications than LV mass itself. Also Miyzato *et al*. \[[@CIT0015]\] in their study of patients with chronic kidney disease noticed increased LV mass.

Systolic function of LV (EF parameter) remained within normal limits in all patients with a noticeable tendency to decrease with the decline in eGFR. EF% was highest in CKD patients stage II, while lowest in stage V/dialysis. Although, this study population consisted of patients with preserved EF, there were significant differences between groups. Also Agarwal *et al*. \[[@CIT0016]\] observed a progressive decline of LV ejection fraction with the increase in severity of renal failure. However, Hayashi *et al*. did not observe significant impairment of systolic function even in patients with severe CKD \[[@CIT0017]\]. According to studies the occurrence of systolic dysfunction of LV varies from 15% to 28% in patients on dialysis \[[@CIT0013], [@CIT0018]\].

In this study it has been analysed whether the progression of renal failure is associated with the HF, i.e. whether significant increase in left ventricular filling pressure, assessed on the basis of the ratio of transmitral early peak diastolic velocity to the early diastolic mitral annulus velocity (E/E') is observed. An E/E' ratio is particularly important in this assessment due to the fact that it reflects LV filling pressure which is the indicator of diastolic dysfunction \[[@CIT0019], [@CIT0020]\]. Numerous studies demonstrated that this ratio was the best non-invasive predictor of elevated LV filling pressure and final diastolic pressure among multiple echocardiographic indices \[[@CIT0021], [@CIT0022]\]. The E/E' ratio \< 8 is considered to be normal, while the ratio \> 15 is considered to mirror the rise in the LV filling pressure \[[@CIT0023], [@CIT0024]\]. Increasing E/E' ratio between groups of patients has been seen in this study. It was lowest in CKD patients stage II (6.7 ±1.5), nearly two times higher in stage IV (11.5 ±4.0) and even greater in dialysis patients before the procedure (13.5 ±5.0). In dialysis patients this ratio was significantly lower after dialysis than before it (*p* = 0.02). Also Masugata *et al*. \[[@CIT0010]\] demonstrated that the E/E' ratio increased with the decrease in eGFR and was significantly higher in CKD patients (16.0 ±6.8) than in those with eGFR \> 90 ml/min/1.73 m \< sup \> 2 \< /sup\>. Pecková *et al*. \[[@CIT0025]\] observed the relationship between two echocardiographic parameters of LV diastolic function (E' and E/E' ratio) and reduced eGFR (stage I--III according to K/DOQI) in patients with type 2 diabetes without a prior history of cardiovascular events. Another study of patients with chronic kidney disease also revealed a significant deteriorated LV diastolic function parameters -- E' and E/E' associated with lower eGFR \[[@CIT0026]\]. Otsuka *et al*. \[[@CIT0007]\] study confirmed that the severity of the kidney dysfunction parallels the rise of E/E' (*p* \< 0.02). Results of a two-dimensional correlation analysis showed the relationship between eGFR and E/E' but not between eGFR and E'. However, according to the results of multivariate analysis both E/E' and E' were independent predictors of eGFR decline. Cluster analysis and ROC curves were used in order to explain this discrepancy and to assess the impact of E' on the relationship between E/E' and eGFR. These analyses showed that E' = 7.1 cm/s is the cut-off point and that the correlation between E/E' and eGFR was significant only for patients with E' ≤ 7.1 cm/s. This means that two different types of patients can be distinguished on the basis of the presence or absence of impaired LV relaxation. Cut-off point E' = 7.1 cm/s corresponds to an age-related border value between the normal and impaired relaxation \[[@CIT0027]\]. The results of another study suggest that abnormal LV relaxation is a factor underlying the relationship between non-invasive parameter E/E' and eGFR. This thesis is confirmed by the fact that there was no significant difference in eGFR between patients with and without abnormal relaxation. On the basis of these results, it can be hypothesized that the improvement of LV relaxation function may prevent or delay the development of heart disease and renal failure abnormalities in patients with uncomplicated type 2 diabetes mellitus \[[@CIT0015]\]. The study by Barberato *et al*. \[[@CIT0028]\] conducted on patients on dialysis revealed that diastolic velocities (early E' and late A') obtained in TDI analysis were 'relatively' independent of preload, did not significantly change after one session of hemodialysis and therefore E' parameter can be particularly useful for dialysis patients to differentiate between pseudonormalization and normal diastolic function profile \[[@CIT0028]\]. The E/E' is of particular importance for the diagnosis of advanced diastolic dysfunction characterized by increased intracellular pressure. The study including 125 renal transplant patients showed that the E/E' \> 15 was an independent predictor of increased LV diastolic blood pressure (\> 15 mm Hg) and was associated with higher overall mortality in this group \[[@CIT0021], [@CIT0022]\].

The analysis of LV diastolic parameters on the basis of E/A ratio revealed that its values were similar in patients CKD stage II--IV which is consistent with adopted standards. However, this ratio was significantly higher in dialysis patients. Also in the study of Otsuka *et al*. \[[@CIT0007]\] mitral E velocity was significantly lower in healthy subjects and CKD patients stage II--IV) (*p* \< 0.01--0.02) compared to stage V, while mitral A velocity was higher in stages II--V (*p* \< 0.01--0.04) than in healthy persons. Moreover, the ratio of mitral E and A velocities (E/A) was significantly higher in healthy patients (*p* \< 0.02--0.05) compared to stages II--V. Otsuka *et al*. \[[@CIT0007]\] suggested that A, E/A and E' could help to differentiate between healthy subjects and patients with early stage of CKD. In this study, E/A ratio did not differ before and after the dialysis.

The reduced deceleration time (DT) along with decreased eGFR was observed in this study. This time was shortest in CKD (excluding ESRD) patients stage IV and longest in II stage. Deceleration time in dialysis patients was much longer than that seen in CKD patients stage II--IV which is probably a result of lower volume overload due to ultrafiltration. Reduced DT as well as decreased values of E/A ratio are indicators of LV diastolic dysfunction and increased LV muscle stiffness. On the basis of obtained results it can be assumed that diastolic LV dysfunction occur in such an early stages of CKD as stage II. Also Otsuka *et al*.\[[@CIT0007]\] in their study observed that DT was significantly longer in healthy subjects and CKD patients stage II (*p* \< 0.01--0.02) than in CKD patients stage IV and V. Furthermore, in their study DT was significantly lower in stage V (*p* \< 0.01) in comparison to stage IV. Diastolic dysfunction seen in CKD patients may precede hypertrophy, as well as the appearance of systolic LV dysfunction.

This study also revealed that the prevalence of left ventricular diastolic dysfunction in the form of relaxation disturbances was high -- 96% in patient with II CKD stage, 96,7% in III stage, 78,6% in IV stage and 54.29% in ESRD. Diastolic dysfunction develops in three phases: inversion of ratio of peak early to peak atrial velocity -- curve, pseudonormalization of E/A flow pattern and finally the development of a restrictive pattern with various degrees of early atrial flow velocity involvement \[[@CIT0019], [@CIT0029]\]. In patients with long-lasting, severe CKD, LV diastolic dysfunction is more frequent in the form of pseudonormal and restrictive filling patterns of LV \[[@CIT0028]\] and thus the percentage of patients with diastolic dysfunction in the form of relaxation disturbances observed in stage IV and V is lower than in earlier stages. In 28.57% of patients with CKD stage V diastolic dysfunction in the form of pseudonormalization was recognized and confirmed by TDI analysis. These patients had the most severe symptoms, significant impairment in exercise tolerance, shortness of breath at rest and periodic leg swelling. Restriction pattern was seen in 17.14% of these patients. According to other studies the incidence of diastolic LV dysfunction in CKD ranges from 50% to 65% including patients non-dialysed, those on dialysis and renal transplant recipients \[[@CIT0030], [@CIT0031]\]. Moreover, some studies have shown that diastolic LV dysfunction precedes systolic function impairment and is responsible for approximately 30--40% of cases of heart failure \[[@CIT0032]\]. The occurrence of diastolic dysfunction without significant impairment of systolic function was also observed in the study of Hayashi *et al*. \[[@CIT0017]\]. On the basis of results obtained in this study it can be assumed that diastolic dysfunction occur in the early stages of CKD -- even in stage 2 (eGFR 89--60 ml/min/1.73 m^2^). Also Otsuka *et al*. study \[[@CIT0007]\] demonstrated that LV diastolic dysfunction was observed even in patients with early stages of chronic kidney dysfunction and suggested that Doppler indices combined with conventional and tissue Doppler methods could detect the subtle changes of diastolic function due to kidney dysfunction. According to Masugata *et al*. \[[@CIT0010]\] LV diastolic function may influence the increase in left ventricular preload as a result of CKD progression. Therefore, LV hypertrophy may be a better prognostic factor than the LV diastolic dysfunction in predicting low eGFR in patients with CKD. The increase in diastolic LV dimension observed in this study as well as very high prevalence of CKD-associated diastolic dysfunction may be an indicator of left ventricular volume overload which is due to over-hydration. This hypothesis is confirmed by the study of London \[[@CIT0030]\] which shows that diastolic dysfunction is a common phenomenon in patients with advanced renal failure and end-stage renal disease due to hypertension and over-hydration. Furthermore, they concluded that renal impairment is associated with diastolic dysfunction regardless of the aetiology of renal failure \[[@CIT0007]\]. Due to the fact that in non-dialysed patients with CKD it is sometimes difficult to control fluid volume (preload) and systemic blood pressure (load), advanced LV diastolic dysfunction observed in patients with kidney disease resulting from diabetic nephropathy suggests that diastolic heart failure in these patients can be induced by heart overload, even despite normal systolic function \[[@CIT0033]--[@CIT0036]\]. Hayashi *et al*.\[[@CIT0017]\] suggested that in patients with advanced renal failure, factors other than LVH may cause diastolic dysfunction since patients with eccentric LVH and with severe renal failure but not patients with mild/moderate renal disease had significantly lower E' compared with controls. Moreover, patients with severe CKD showed more pronounced diastolic dysfunction than patients with mild/moderate CKD and controls though the prevalence of LVH did not differ between the groups \[[@CIT0017]\]. Although LV filling abnormalities are frequently reported in patients with CKD, their prognostic significance is not known in this group of patients \[[@CIT0037]\]. Nevertheless, it is common that left ventricular hypertrophy is a predictor of cardiovascular complications in patients with hypertension and CKD but the relationship between the echocardiographic parameters and renal function still are not fully explored \[[@CIT0038], [@CIT0039]\].

In CKD patients, left ventricular hypertrophy (LVH) is a common finding and it is associated with an increased CVD-related mortality \[[@CIT0017], [@CIT0040]\]. In this study, LV hypertrophy was observed in all patients, but it was slightly more pronounced in patients with stage IV and V. The occurrence of LVH in this study was higher compared to that observed by Hayashi *et al*. \[[@CIT0017]\] -- 63% in CKD patients stage I, II and III and 66% in CKD stage IV--V. Studies indicates that the prevalence of LVH increases to 60--75% in patients beginning renal replacement therapy, and reaches 70--90% in patients on regular dialysis \[[@CIT0041], [@CIT0042]\]. According to Levin *et al*.\[[@CIT0043]\] the prevalence and severity of LVH increases along with the progression of chronic kidney disease. At first, LVH is a physiological response to pressure and volume overload, but then when combined with anaemia and hyperparathyroidism it may turn into maladaptive LVH characterized by structural changes in the myocardium, such as collagen accumulation, fibrosis and calcification, which lead to systolic and diastolic dysfunction \[[@CIT0017], [@CIT0030], [@CIT0044]\]. In patients on dialysis arteriovenous fistula reduces systemic vascular resistance \[[@CIT0045]\] and increases stroke volume load on the left ventricle which may contributes to LVH and may results in LV systolic and diastolic dysfunction with time \[[@CIT0046], [@CIT0047]\]. Also Rosello *et al*.\[[@CIT0048]\] suggested that LVH contribute to diastolic LV dysfunction. According to Masugata *et al*. \[[@CIT0010]\], LV hypertrophy may be superior to LV diastolic dysfunction in predicting low eGFR in patients with CKD using echocardiography. Hayashi *et al*. \[[@CIT0017]\] suggested that LV geometry can affect systolic function since eccentric LVH has been described to be more frequently associated with systolic dysfunction than concentric LVH \[[@CIT0017]\]. However, in this study systolic function remained within normal limits in all patients, even in those with end-stage renal disease.

The limitation of this study is the fact that the number of subjects was relatively small and all patients came from a single centre and thus there is a possibility of bias in the selection process. Greater study group is needed to produce a more accurate representation of the prevalence of diastolic dysfunction in CKD. Moreover, our study population consisted of CKD patients with normal LV EF \[[@CIT0047]--[@CIT0051]\].

In conclusion, in CKD patients maladaptive events leading to LVH, structural changes myocardium as well as diastolic dysfunction and even systolic failure occur frequently. Thus, early identification and treatment of factors involved in order to prevent this devastating process. Many indexes of contractility have been developed and each of them has imperfections. Now it seems that TVI and E, E/A and E/E' parameters are good instruments for the early detection of LVH and diastolic dysfunction as they are important risk factors for cardiovascular morbidity and mortality in CKD.
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